David Schnell

4.1k total citations
86 papers, 1.7k citations indexed

About

David Schnell is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, David Schnell has authored 86 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Pulmonary and Respiratory Medicine, 27 papers in Oncology and 16 papers in Epidemiology. Recurrent topics in David Schnell's work include Lung Cancer Treatments and Mutations (16 papers), HER2/EGFR in Cancer Research (13 papers) and Acute Kidney Injury Research (11 papers). David Schnell is often cited by papers focused on Lung Cancer Treatments and Mutations (16 papers), HER2/EGFR in Cancer Research (13 papers) and Acute Kidney Injury Research (11 papers). David Schnell collaborates with scholars based in France, Germany and United Kingdom. David Schnell's co-authors include Michaël Darmon, Élie Azoulay, Sven Wind, Peter Stopfer, Emmanuel Canet, Fabrice Zéni, Thomas Ebner, Matthias Freiwald, Ferhat Meziani and Jérôme Lambert and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

David Schnell

80 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Schnell France 23 627 406 403 367 328 86 1.7k
György Frendl United States 25 504 0.8× 250 0.6× 307 0.8× 144 0.4× 438 1.3× 58 2.3k
Michael Fischereder Germany 30 448 0.7× 518 1.3× 602 1.5× 611 1.7× 767 2.3× 121 3.3k
Anne Boutten France 28 644 1.0× 352 0.9× 390 1.0× 454 1.2× 325 1.0× 65 3.0k
Jonathan Janes United States 25 306 0.5× 294 0.7× 1.4k 3.5× 226 0.6× 387 1.2× 50 3.7k
Taekyu Hwang United States 7 264 0.4× 187 0.5× 1.1k 2.6× 202 0.6× 345 1.1× 8 2.1k
Peter Schellongowski Austria 20 422 0.7× 300 0.7× 310 0.8× 66 0.2× 332 1.0× 66 1.5k
Nick Anas United States 28 892 1.4× 138 0.3× 958 2.4× 150 0.4× 414 1.3× 52 2.1k
M C Allison United Kingdom 27 805 1.3× 350 0.9× 515 1.3× 169 0.5× 1.0k 3.1× 63 2.9k
Julie Ho Canada 28 247 0.4× 249 0.6× 718 1.8× 1.1k 3.1× 1.6k 4.8× 88 3.8k
Jérôme Stirnemann France 26 399 0.6× 100 0.2× 614 1.5× 134 0.4× 311 0.9× 149 2.9k

Countries citing papers authored by David Schnell

Since Specialization
Citations

This map shows the geographic impact of David Schnell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Schnell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Schnell more than expected).

Fields of papers citing papers by David Schnell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Schnell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Schnell. The network helps show where David Schnell may publish in the future.

Co-authorship network of co-authors of David Schnell

This figure shows the co-authorship network connecting the top 25 collaborators of David Schnell. A scholar is included among the top collaborators of David Schnell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Schnell. David Schnell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Valette, Xavier, Agathe Delbove, David Schnell, et al.. (2025). Life-Supporting Treatment Limitations in Patients Who Die Within 48 Hours After ICU Admission: A French, Multicenter, Observational, Exploratory Study. Critical Care Explorations. 7(8). e1300–e1300.
2.
Cui, Yunhai, et al.. (2020). In-Depth Characterization of EpiIntestinal Microtissue as a Model for Intestinal Drug Absorption and Metabolism in Human. Pharmaceutics. 12(5). 405–405. 30 indexed citations
3.
Jonge, Maja J.A. de, Neeltje Steeghs, Martijn P. Lolkema, et al.. (2019). Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies. Targeted Oncology. 14(1). 43–55. 47 indexed citations
4.
Bahleda, Rastislav, Andréa Varga, Yann Bergé, et al.. (2018). Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2. British Journal of Cancer. 118(3). 344–352. 7 indexed citations
5.
Palmer, Daniel H., Yuk Ting, Markus Peck‐Radosavljevic, et al.. (2018). A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma. British Journal of Cancer. 118(9). 1162–1168. 26 indexed citations
6.
Perier, François, David Schnell, Sybille Merceron, et al.. (2018). Comparison of etomidate and sodium thiopental for induction during rapid sequence intubation in convulsive status epilepticus: A retrospective single-center study. Seizure. 61. 170–176. 3 indexed citations
7.
Wei, Xiaowei, Yong Xu, Luksana Chaiswing, et al.. (2017). RelB Expression Determines the Differential Effects of Ascorbic Acid in Normal and Cancer Cells. Cancer Research. 77(6). 1345–1356. 37 indexed citations
8.
Cantais, Aymeric, David Schnell, F. Vincent, et al.. (2016). Acetaminophen-Induced Changes in Systemic Blood Pressure in Critically Ill Patients: Results of a Multicenter Cohort Study. Critical Care Medicine. 44(12). 2192–2198. 38 indexed citations
9.
Suder, Aneta, J.E. Ang, Sarah Rudman, et al.. (2015). A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours. European Journal of Cancer. 51(16). 2275–2284. 22 indexed citations
10.
Schnell, David, et al.. (2015). Doppler-based renal resistive index for prediction of renal dysfunction reversibility: A systematic review and meta-analysis. Journal of Critical Care. 30(3). 629–635. 81 indexed citations
11.
Schöffski, Patrick, Philippe Aftimos, Herlinde Dumez, et al.. (2015). A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 77(1). 99–108. 14 indexed citations
12.
Schnell, David, Holger Fuchs, Dietmar Ganßer, et al.. (2014). Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment. Cancer Chemotherapy and Pharmacology. 74(2). 267–275. 32 indexed citations
13.
Ring, Alistair, Duncan Wheatley, Helen Hatcher, et al.. (2014). Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer. Clinical Cancer Research. 21(12). 2737–2744. 16 indexed citations
14.
Chu, Quincy S., Randeep Sangha, Sébastien J. Hotte, et al.. (2014). A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors. Investigational New Drugs. 32(6). 1226–1235. 7 indexed citations
15.
Schnell, David, Maud Gits‐Muselli, Emmanuel Canet, et al.. (2013). Burden of respiratory viruses in patients with acute respiratory failure. Journal of Medical Virology. 86(7). 1198–1202. 17 indexed citations
16.
Schmidt, Matthieu, Romain Sonneville, David Schnell, et al.. (2013). Clinical Features and Outcomes in Patients With Disseminated Toxoplasmosis Admitted to Intensive Care: A Multicenter Study. Clinical Infectious Diseases. 57(11). 1535–1541. 34 indexed citations
17.
Schnell, David, Laurent Arnaud, Virginie Lemiale, & Stéphane Legriel. (2012). Pupillary hippus in nonconvulsive status epilepticus. Epileptic Disorders. 14(3). 310–312. 5 indexed citations
18.
Mariotte, Éric, David Schnell, Catherine Scieux, et al.. (2011). Significance of herpesvirus 6 in BAL fluid of hematology patients with acute respiratory failure. Infection. 39(3). 225–230. 14 indexed citations
19.
Zahar, Jean‐Ralph, Emmanuelle Bille, David Schnell, et al.. (2009). Diffusion communautaire des entérobactéries sécrétrices de β-lactamase à spectre élargi (EBLSE). médecine/sciences. 25(11). 939–944. 13 indexed citations
20.
Schnell, David, et al.. (1987). Organerhaltendes Vorgehen bei gutartigem Hodentumor?. Aktuelle Urologie. 18(3). 127–132. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by György Frendl Breakdown of academic impact, for papers by Michael Fischereder Breakdown of academic impact, for papers by Anne Boutten Breakdown of academic impact, for papers by Jonathan Janes Breakdown of academic impact, for papers by Taekyu Hwang Breakdown of academic impact, for papers by Peter Schellongowski Breakdown of academic impact, for papers by Nick Anas Breakdown of academic impact, for papers by M C Allison Breakdown of academic impact, for papers by Julie Ho Breakdown of academic impact, for papers by Jérôme Stirnemann
Rankless by CCL
2026